SDC1 and Miyoshi myopathy: To test the sensitivity of primary vs. relapsed myeloma specimens to MTI-101, CD138-positive malignant plasma cell fractions from thirteen newly diagnosed and twelve relapsed primary MM specimens were treated with MTI-101.